Efficacy and Safety of Gamma Knife Radiosurgery for Meningiomas in Patients with Neurofibromatosis Type 2: A Long-Term Follow-Up Single-Center Study
Overview
Affiliations
Objective: To explore the efficacy and safety of Gamma Knife radiosurgery (GKRS) for meningiomas in patients with neurofibromatosis type 2 (NF2).
Methods: A series of 35 consecutive patients with 99 meningiomas in our department were retrospectively included from January 2000 to December 2015. Clinical records, magnetic resonance images, and follow-up data were reviewed.
Results: A total of 35 patients (25 women and 10 men) with 99 NF2-associated meningiomas were identified. All patients initially received GKRS. The patients' median age at the time of GKRS was 40 years (range, 16-61 years). The median prescription dose at the tumor margin was 13 Gy (range, 12-15 Gy). The median follow-up time was 96 months (range, 25-224 months). Twenty-nine patients received GKRS only once, and 6 patients received it multiple times. Six patients (17.1%) had radiation-related complications 7.5 ± 2.4 months after GKRS. Local control rates at 1, 3, and 5 years were 100%, 97.1%, and 90.6%, respectively. Distant control rates at 1, 3, and 5 years were 88.5%, 55.9%, and 45.5%, respectively. Five patients died of concomitant neurologic symptoms. No malignant transformation was observed during the follow-up periods in all 35 patients.
Conclusions: GKRS represents an effective and safe management strategy with minimal invasion for patients with NF2-associated meningiomas. Our data showed a high local control rate of NF2-associated meningiomas by GKRS; however, the distant control rate is low, especially in young patients. For these patients, retreatment with GKRS may still be the advisable method.
Habibi M, Mirjani M, Ahmadvand M, Delbari P, Alasti O, Akbari Javar M Acta Neurochir (Wien). 2025; 167(1):35.
PMID: 39907804 PMC: 11799078. DOI: 10.1007/s00701-025-06436-4.
Wang J, Landry A, Raleigh D, Sahm F, Walsh K, Goldbrunner R Neuro Oncol. 2024; 26(10):1742-1780.
PMID: 38695575 PMC: 11449035. DOI: 10.1093/neuonc/noae082.
The clinical, genetic, and immune landscape of meningioma in patients with NF2-schwannomatosis.
Gregory G, Islim A, Hannan C, Jones A, Hammerbeck-Ward C, Rutherford S Neurooncol Adv. 2023; 5(Suppl 1):i94-i104.
PMID: 37287576 PMC: 10243851. DOI: 10.1093/noajnl/vdac127.
Ruiz-Garcia H, Trifiletti D, Mohammed N, Hung Y, Xu Z, Chytka T J Neurol Surg B Skull Base. 2022; 83(Suppl 2):e173-e180.
PMID: 35832959 PMC: 9272243. DOI: 10.1055/s-0041-1722937.
Tosi U, Maayan O, An A, Tusa Lavieri M, Guadix S, DeRosa A J Neurooncol. 2022; 156(2):431-441.
PMID: 35040021 DOI: 10.1007/s11060-021-03910-8.